Dr. Phillips, of the City of Hope National Medical Center, discusses a phase I/II study of glofitamab monotherapy in patients with mantle cell lymphoma (MCL) presented at the 2024 American Society of Clinical Oncology Annual Meeting.

Dr. Phillips and colleagues noted similar overall response rates (ORRs) and complete response (CR) rates in patients who received prior Bruton’s tyrosine kinase (BTK) inhibitor therapy and those who did not. The ORR and CR rate were 85.0% and 78.3%, respectively. The 15month progressionfree survival was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.

The researchers also conducted a landmark analysis of patients who maintained a CR at the end of treatment.

“Over half of those patients had durability of response, suggesting that this could be a very durable treatment for these patients despite not having continuation of therapy, as glofitamab was given for a finite period of about 8.3 months,” Dr. Phillips explained.

Cytokine release syndrome (CRS) was the most common adverse event, occurring in 70% of patients. However, the researchers observed a decrease in the incidence and severity of CRS when patients were given obinutuzumab 2 g prior to glofitamab compared with obinutuzumab 1 g.

“After the initial stepup period, this treatment was relatively safe,” Dr. Phillips said.